Pioglitazone enhances the antihypertensive and renoprotective effects of candesartan in Zucker obese rats fed a high-protein diet

Hypertension Research

Volumn 31, Issue 4, 2008, Pages 745-755

  Namikoshi, Tamehachi ^a   Tomita, Naruya ^a   Satoh, Minoru ^a   Haruna, Yoshisuke ^a   Kobayashi, Shinya ^a   Komai, Norio ^a   Sasaki, Tamaki ^a   Kashihara, Naoki ^a  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

Angiotensin II type 1 receptor blocker; Dietary protein; Thiazolidinediones; Tubulointerstitial injury

Indexed keywords

CANDESARTAN; HYDRALAZINE; PIOGLITAZONE;

ANIMAL EXPERIMENT; ANIMAL FOOD; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG URINE LEVEL; FIBROSING ALVEOLITIS; GLOMERULOSCLEROSIS; HISTOPATHOLOGY; HYPERTENSION; IMMUNOHISTOCHEMISTRY; KIDNEY INJURY; KIDNEY INTERSTITIUM; MACROPHAGE; MALE; METABOLIC SYNDROME X; MONOCYTE; MONOTHERAPY; NONHUMAN; OBESITY; PROTEIN DIET; PROTEIN URINE LEVEL; PROTEINURIA; RAT; RENAL PROTECTION; SYSTOLIC BLOOD PRESSURE; ZUCKER RAT;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BLOOD PRESSURE; DIETARY PROTEINS; DRUG SYNERGISM; HYPERTENSION, RENAL; HYPOGLYCEMIC AGENTS; IMMUNOHISTOCHEMISTRY; KIDNEY; MALE; METABOLIC SYNDROME X; OBESITY; RATS; RATS, ZUCKER; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; TETRAZOLES; THIAZOLIDINEDIONES;

EID: 44649160542     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1291/hypres.31.745     Document Type: Article

References (45)

1. Lakka HM, Laaksonen DE, Lakka TA, et al: The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288: 2709-2716.
2. Isomaa B, Almgren P, Tuomi T, et al: Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 683-689.
3. Chen J, Muntner P, Hamm LL, et al: The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med 2004; 140: 167-174.
4. Kurella M, Lo JC, Chertow GM: Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J Am Soc Nephrol 2005; 16: 2134-2140.
5. Tanaka H, Shiohira Y, Uezu Y, Higa A, Iseki K: Metabolic syndrome and chronic kidney disease in Okinawa, Japan. Kidney Int 2006; 69: 369-374.
6. Ruster C, Wolf G: Renin-angiotensin-aldosterone system and progression of renal disease. J Am Soc Nephrol 2006; 17: 2985-2991.
7. Karalliedde J, Viberti G: Evidence for renoprotection by blockade of the renin-angiotensin-aldosterone system in hypertension and diabetes. J Hum Hypertens 2006; 20: 239-253.
8. Derosa G, Cicero AF, Dangelo A, et al: Thiazolidinedione effects on blood pressure in diabetic patients with metabolic syndrome treated with glimepiride. Hypertens Res 2005; 28: 917-924.
9. Sarafidis PA, Bakris GL: Protection of the kidney by thiazolidinediones: an assessment from bench to bedside. Kidney Int 2006; 70: 1223-1233.
10. Kiberd B: The chronic kidney disease epidemic: stepping back and looking forward. J Am Soc Nephrol 2006; 17: 2967-2973.
11. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305.
12. Zucker LM: Hereditary obesity in the rat associated with hyperlipemia. Ann N Y Acad Sci 1965; 131: 447-458.
13. Kasiske BL, O'Donnell MP, Keane WF: The Zucker rat model of obesity, insulin resistance, hyperlipidemia, and renal injury. Hypertension 1992; 19 (Suppl 1): I110-I115.
14. Kasiske BL, Cleary MP, O'Donnell MP, Keane WF: Effects of genetic obesity on renal structure and function in the Zucker rat. J Lab Clin Med 1985; 106: 598-604.
15. Alavi FK, Zawada ET, Simmons JL: Renal hemodynamic and histological consequences of diets high in unsaturated fat, protein or sucrose in obese Zucker rats. Clin Nephrol 1995; 43: 122-130.
16. Mizuno M, Sada T, Kato M, Koike H: Renoprotective effects of blockade of angiotensin II AT1 receptors in an animal model of type 2 diabetes. Hypertens Res 2002; 25: 271-278.
17. Schmitz PG, O'Donnell MP, Kasiske BL, Katz SA, Keane WF: Renal injury in obese Zucker rats: glomerular hemodynamic alterations and effects of enalapril. Am J Physiol 1992; 263: F496-F502.
18. Yoshimoto T, Naruse M, Nishikawa M, et al: Antihypertensive and vasculo- and renoprotective effects of pioglitazone in genetically obese diabetic rats. Am J Physiol 1997; 272: E989-E996.
19. Buckingham RE, Al-Barazanji KA, Toseland CD, et al: Peroxisome proliferator-activated receptor-γ agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats. Diabetes 1998; 47: 1326-1334.
20. Baylis C, Atzpodien EA, Freshour G, Engels K: Peroxisome proliferator-activated receptor γ agonist provides superior renal protection versus angiotensin-converting enzyme inhibition in a rat model of type 2 diabetes with obesity. J Pharmacol Exp Ther 2003; 307: 854-860.
21. Tomita N, Higaki J, Kaneda Y, et al: Hypertensive rats produced by in vivo introduction of the human renin gene. Circ Res 1993; 73: 898-905.
22. Namikoshi T, Tomita N, Fujimoto S, et al: Isohumulones derived from hops ameliorate renall injury via an anti-oxidative effect in Dahl salt-sensitive rats. Hypertens Res 2007; 30: 175-184.
23. Coimbra TM, Janssen U, Grone HJ, et al: Early events leading to renal injury in obese Zucker (fatty) rats with type II diabetes. Kidney Int 2000; 57: 167-182.
24. Palmer BF: Disturbances in renal autoregulation and the susceptibility to hypertension-indqced chronic kidney disease. Am J Med Sci 2004; 328: 330-343.
25. Dubey RK, Zhang HY, Reddy SR, Boegehold MA, Kotchen TA: Pioglitazone attenuates hypertension and inhibits growth of renal arteriolar smooth muscle in rats. Am J Physiol 1993; 265: R726-R732.
26. Hayashi K, Kanda T, Homma K, et al: Altered renal microvascular response in Zucker obese rats. Metabolism 2002; 51: 1553-1561.
27. Rodriguez WE, Tyagi N, Joshua IG, et al: Pioglitazone mitigates renal glomerular vascular changes in high-rat, high-calorie-induced type 2 diabetes mellitus. Am J Physiol Renal Physiol 2006; 291: F694-F701.
28. Zhang HY, Reddy SR, Kotchen TA: Antihypertensive effect of pioglitazone is not invariably associated with increased insulin sensitivity. Hypertension 1994; 24: 106-110.
29. Iida KT, Kawakami Y, Suzuki M, et al: Effect of thiazolidinediones and metformin on LDL oxidation and aortic endothelium relaxation in diabetic GK rats. Am J Physiol Endocrinol Metab 2003; 284: E115-E1130.
30. Dobrian AD, Schriver SD, Khraibi AA, Prewitt RL: Pioglitazone prevents hypertension and reduces oxidative stress in diet-induced obesity. Hypertension 2004; 43: 48-56.
31. Calnek DS, Mazzella L, Roser S, Roman J, Hart CM: Peroxisome proliferator-activated receptor γ ligands increase release of nitric oxide from endothelial cells. Arterioscler Thromb Vasc Biol 2003; 23: 52-57.
32. Cho DH, Choi YJ, Jo SA, Jo I: Nitric oxide production and regulation of endothelial nitric-oxide synthase phosphorylation by prolonged treatment with troglitazone: evidence for involvement of peroxisome proliferator-activated receptor (PPAR) γ-dependent and PPARγ-independent signaling pathways. J Biol Chem 2004; 279: 2499-2506.
33. Wakino S, Hayashi K, Tatematsu S, et al: Pioglitazone lowers systemic asymmetric dimethylarginine by inducing dimethylarginine dimethylamino-hydrolase in rats. Hypertens Res 2005; 28: 255-262.
34. Arima S, Kohagura K, Takeuchi K, et al: Biphasic vasodilator action of troglitazone on the renal microcirculation. J Am Soc Nephrol 2002; 13: 342-349.
35. Xu ZG, Lanting L, Vaziri ND, et al: Upregulation of angiotensin IItype I receptor, inflammatory mediators, and enzymes of arachidonate metabolism in obese Zucker rat kidney: reversal by angiotensin II type I receptor blockade. Circulation 2005; 111: 1962-1969.
36. Diep QN, El Mabrouk M, Cohn JS, et al: Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-γ. Circulation 2002; 105: 2296-2302.
37. Wolf G, Chen S, Ziyadeh FN: From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy. Diabetes 2005; 54: 1626-1634.
38. Benigni A, Zoja C, Tomasoni S, et al: Transcriptional regulation of nephrin gene by peroxisome proliferator-activated receptor-γ agonist: molecular mechanism of the antiproteinuric effect of pioglitazone. J Am Soc Nephrol 2006; 17: 1624-1632.
39. Abbate M, Zoja C, Remuzzi G: How does proteinuria cause progressive renal damage? J Am Soc Nephrol 2006; 17: 2974-2984.
40. Ma LJ, Marcantoni C, Linton MF, Fazio S, Fogo AB: Peroxisome proliferator-activated receptor-γ agonist troglitazone protects against nondiabetic glomerulosclerosis in rats. Kidney Int 2001; 59: 1899-1910.
41. Zafiriou S, Stanners SR, Saad S, Polhill TS, Poronnik P, Pollock CA: Pioglitazone inhibits cell growth and reduces matrix production in human kidney fibroblasts. J Am Soc Nephrol 2005; 16: 638-645.
42. Li Y, Wen X, Spataro BC, Hu K, Dai C, Liu Y: Hepatocyte growth factor is a downstream effector that mediates the antifibrotic action of peroxisome proliferator-activated receptor-γ agonists. J Am Soc Nephrol 2006; 17: 54-65.
43. Pasceri V, Wu HD, Willerson JT, Yeh ET: Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-γ activators. Circulation 2000; 101: 235-238.
44. Ishibashi M, Egashira K, Hiasa K, et al: Antiinflammatory and antiarteriosclerotic effects of pioglitazone. Hypertension 2002; 40: 687-693.
45. Namikoshi T, Satoh M, Tomita N, et al: Pioglitazone ameliorates endothelial dysfunction in obese rats with nephropathy. Biochem Biophys Res Commun 2007; 361: 835-840.